Chroma Medicine

Chroma Medicine company information, Employees & Contact Information

Explore related pages

Related company profiles:

Chroma Medicine is pioneering a new class of single-dose genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, revolutionizing the treatment of disease. Epigenetics is nature’s central mechanism for gene regulation, governing cell phenotype and function by precisely controlling gene activity without changing the underlying DNA sequence. Building on groundbreaking research from the world’s foremost genomic medicine experts, Chroma Medicine is working at the cutting edge of precision genomics, building an entirely new class of therapeutics to achieve unparalleled control of gene expression. *Note: Be aware of fraudulent recruiting advertisements and scams: Potential candidates for employment at Chroma Medicine should be aware of job offer fraud scams perpetrated through the use of the internet and social media platforms. To learn more, please visit the Join Us page on our website.

Company Details

Employees
30
Founded
-
Address
201 Brookline Avenue,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
jobs.
HQ
Boston, Massachusetts
Looking for a particular Chroma Medicine employee's phone or email?

Chroma Medicine Questions

News

Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines - Business Wire

Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines Business Wire

Chroma Medicine, Nvelop Therapeutics Merge as nChroma Bio with Focus on Epigenetic Therapies - Genetic Engineering and Biotechnology News

Chroma Medicine, Nvelop Therapeutics Merge as nChroma Bio with Focus on Epigenetic Therapies Genetic Engineering and Biotechnology News

Gene-editing field sees another merger, this time between Chroma Medicine and Nvelop Therapeutics - statnews.com

Gene-editing field sees another merger, this time between Chroma Medicine and Nvelop Therapeutics statnews.com

Chroma Medicine, Nvelop Therapeutics merge to form nChroma Bio - Chemical & Engineering News

Chroma Medicine, Nvelop Therapeutics merge to form nChroma Bio Chemical & Engineering News

Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines - Sixth Street

Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines Sixth Street

Chroma Medicine Appoints Renowned RNA Scientist Melissa Moore to Board of Directors - PR Newswire

Chroma Medicine Appoints Renowned RNA Scientist Melissa Moore to Board of Directors PR Newswire

Chroma Medicine Appoints Jenny Marlowe, Ph.D., as Chief Development Officer - citybiz

Chroma Medicine Appoints Jenny Marlowe, Ph.D., as Chief Development Officer citybiz

Genomic medicine company Chroma raises $135M - Labiotech.eu

Genomic medicine company Chroma raises $135M Labiotech.eu

Wilson Sonsini Advises Chroma Medicine on $135 Million Series B Financing - Wilson Sonsini

Wilson Sonsini Advises Chroma Medicine on $135 Million Series B Financing Wilson Sonsini

Chroma Medicine and Tune Therapeutics: Two companies take up epigenome editing - Nature

Chroma Medicine and Tune Therapeutics: Two companies take up epigenome editing Nature

Gene on, gene off: Chroma Medicine turns lights on with $125M to control gene expression with ex-Editas, Regeneron leaders - Fierce Biotech

Gene on, gene off: Chroma Medicine turns lights on with $125M to control gene expression with ex-Editas, Regeneron leaders Fierce Biotech

Chroma Scores $135M for Epigenetic Editing Approach - BioSpace

Chroma Scores $135M for Epigenetic Editing Approach BioSpace

Amid industry turbulence, Chroma raises fresh funding to edit the epigenome - BioPharma Dive

Amid industry turbulence, Chroma raises fresh funding to edit the epigenome BioPharma Dive

Epigenetic editing startup Chroma lays off staff, focusing on reaching the clinic - Endpoints News

Epigenetic editing startup Chroma lays off staff, focusing on reaching the clinic Endpoints News

Chroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75M - BioXconomy

Chroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75M BioXconomy

Chroma Medicine Appoints Jeff Marrazzo to Board of Directors - citybiz

Chroma Medicine Appoints Jeff Marrazzo to Board of Directors citybiz

Up or Down: Chroma Medicine Raises Stakes in Epigenetic Editing - Genetic Engineering and Biotechnology News

Up or Down: Chroma Medicine Raises Stakes in Epigenetic Editing Genetic Engineering and Biotechnology News

Chroma bags another 9-digit financing, taking $135M series B to bolster epigenetic-focused platform - Fierce Biotech

Chroma bags another 9-digit financing, taking $135M series B to bolster epigenetic-focused platform Fierce Biotech

Chroma to pioneer epigenetic editors - Nature

Chroma to pioneer epigenetic editors Nature

Chroma Medicine raises $135 million for its epigenetic editing therapies - The Boston Globe

Chroma Medicine raises $135 million for its epigenetic editing therapies The Boston Globe

Former Spark Therapeutics CEO Jeff Marrazzo joins board of Cambridge genomics company - The Business Journals

Former Spark Therapeutics CEO Jeff Marrazzo joins board of Cambridge genomics company The Business Journals

Top Chroma Medicine Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant